Internal Medicine, Hematology & Oncology · Kingwood, TX
NPI
1841459773
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
4
Hospital affiliations
22751 Professional Dr Ste 110
Kingwood, TX, 77339
Phone (281) 440-5300
Groups this clinician bills Medicare through
Medicare paid, 2024
$715K
53,541 services
Medicare patients, 2024
178
Average age 74
Drug cost, 2024
$4.2M
1,144 prescriptions
Company payments, 2025
$4,918
From 40 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Saleha S Sajid was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 15,300 times for 14 patients. In total Saleha S Sajid billed 53,541 services in 64 codes, and Medicare paid $715K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-06-30.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 15,300 | 14 | $0.28 | $4,291 |
| 99214 Office E&M - Established | Office | 433 | 163 | $94.22 | $41K |
| 96367 Intravenous Infusion, Hydration | Office | 280 | 24 | $22.55 | $6,315 |
| 96413 Chemotherapy Administration | Office | 125 | 14 | $100.98 | $13K |
| J1200 Injection, diphenhydramine hcl, up to 50 mg | Office | 96 | 22 | $0.66 | $63.35 |
| 96127 Behavioral Health Services | Office | 60 | 59 | $3.78 | $227 |
| 96372 Injection Administration | Office | 56 | 12 | $10.66 | $597 |
| 99205 Office E&M - New | Office | 55 | 55 | $164.36 | $9,040 |
| 96365 Intravenous Infusion, Hydration | Office | 45 | 18 | $49.96 | $2,248 |
By year: 2022 $249K for 43,673 services; 2023 $378K for 47,606 services; 2024 $715K for 53,541 services.
Medicare prescription drug claims, 2024
In 2024, the drug Saleha S Sajid prescribed most often to Medicare patients was Anastrozole, with 81 prescriptions and refills. In total Saleha S Sajid wrote 1,144 Medicare prescriptions that cost $4.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 81 | 180 | 24 | $1,066 |
| Dexamethasone Generic | 45 | 52 | 20 | $710 |
| Neulasta Onpro Pegfilgrastim | 38 | 38 | Under 11 | $236K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 35 | 35 | 15 | $897 |
| Ondansetron Odt Ondansetron | 35 | 35 | 19 | $469 |
| Eliquis Apixaban | 31 | 41 | Under 11 | $24K |
| Prednisone Generic | 30 | 36 | Under 11 | $166 |
| Xtandi Enzalutamide | 26 | 26 | Under 11 | $323K |
| Alprazolam Generic | 26 | 26 | Under 11 | $200 |
| Imbruvica Ibrutinib | 26 | 26 | Under 11 | $394K |
| Nyvepria Pegfilgrastim-Apgf | 25 | 25 | Under 11 | $101K |
| Verzenio Abemaciclib | 25 | 25 | Under 11 | $385K |
| Venlafaxine Hcl Generic | 24 | 26 | Under 11 | $242 |
| Zarxio Filgrastim-Sndz | 20 | 20 | Under 11 | $26K |
| Zolpidem Tartrate Generic | 19 | 25 | Under 11 | $207 |
Brand drugs: 431 claims; generic drugs: 713 claims; opioid claims: 76.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Saleha S Sajid $4,918 ($4,918 in general payments such as food, travel and fees) from 40 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $3,064.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 7 | $3,064 |
| Pfizer Inc. PFE | 7 | $178 |
| Janssen Biotech, Inc. JNJ | 8 | $169 |
| Celgene Corporation BMY | 3 | $96.28 |
| Tempus AI, Inc TEM | 4 | $94.75 |
| E.R. Squibb & Sons, L.L.C. BMY | 4 | $91.78 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $91.04 |
| Regeneron Healthcare Solutions, Inc. REGN | 4 | $87.05 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $80.71 |
| TerSera Therapeutics LLC | 3 | $78.53 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.